Literature DB >> 9647215

Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.

T K Tarrant1, P B Silver, C C Chan, B Wiggert, R R Caspi.   

Abstract

Experimental autoimmune uveitis (EAU) has been associated with a Th1 response. However, in IFN-gamma-deficient mice, EAU develops in the context of an effector response having Th2-like elements, and administration of IL-12 to mice immunized for EAU induction can be protective. We, therefore, investigated whether endogenous IL-12 is required for development of EAU. IL-12 p40-deficient mice (12KO) were resistant to EAU induced with the uveitogenic retinal Ag interphotoreceptor retinoid binding protein (IRBP). Delayed hypersensitivity to IRBP was marginally reduced, whereas Ag-specific proliferation was enhanced. Primed lymphocytes of wild-type (wt) mice, cultured with IRBP, produced a Th1-like cytokine profile and transferred EAU to syngeneic wt recipients. Interestingly, the same cells were inefficient in transferring EAU to 12KO recipients, unless IL-12 was included in the culture. Primed cells of the 12KO mice produced a Th2-like cytokine profile and failed to transfer EAU. However, when IL-12 was added to the culture, 12KO cells produced large amounts of IFN-gamma and transferred EAU to naive 12KO recipients. We conclude that resistance to EAU of 12KO mice is not due to an inherent inability of these mice to develop ocular disease. Despite an apparent similarity in Ag-specific cytokine responses to IFN-gamma-deficient mice, 12KO mice have inhibited generation of uveitogenic effector cells, a situation that can be reversed even after priming, by adding exogenous IL-12 ex vivo. Lastly, the diminished ability of primed wt lymphocytes to induce EAU in 12KO mice indicates a role for endogenous IL-12 in the efferent phase of disease expression that is distinct from its role during Ag priming.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647215

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Immune mechanisms in uveitis.

Authors:  R R Caspi
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  In vivo imaging of the immune response in the eye.

Authors:  Doran B Spencer; Ellen J Lee; Tatsushi Kawaguchi; James T Rosenbaum
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 4.  IL12Rβ1: the cytokine receptor that we used to know.

Authors:  Richard T Robinson
Journal:  Cytokine       Date:  2014-12-13       Impact factor: 3.861

Review 5.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

Review 6.  Cytokines in posterior uveitis: an update.

Authors:  V K Singh; G Rai
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

7.  Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.

Authors:  R K Agarwal; Y Kang; E Zambidis; D W Scott; C C Chan; R R Caspi
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 8.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

9.  Combined cyclosporin-A /prednisone therapy of patients with active uveitis suppresses IFN-gamma production and the function of dendritic cells.

Authors:  M A Frassanito; R Dammacco; T Fusaro; A Cusmai; S Guerriero; C Sborgia
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Upregulated IL-21 and IL-21 receptor expression is involved in experimental autoimmune uveitis (EAU).

Authors:  Lan Liu; Yongfeng Xu; Jianyong Wang; Huiyan Li
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.